Telomir Pharmaceuticals, Company Leadership
| TELO Stock | 4.28 0.17 3.82% |
Telomir Pharmaceuticals, employs about 1 people. The company is managed by 7 executives with a total tenure of roughly 3 years, averaging almost 0.0 years of service per executive, having 0.14 employees per reported executive. Analysis of Telomir Pharmaceuticals,'s management performance can provide insight into the firm performance.
Telomir |
Telomir Pharmaceuticals, Management Team Effectiveness
The company has return on total asset (ROA) of (0.8449) % which means that it has lost $0.8449 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.8691) %, meaning that it created substantial loss on money invested by shareholders. Telomir Pharmaceuticals,'s management efficiency ratios could be used to measure how well Telomir Pharmaceuticals, manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Tangible Assets is likely to drop to -2.88. In addition to that, Return On Capital Employed is likely to grow to -1.09. At this time, Telomir Pharmaceuticals,'s Total Assets are very stable compared to the past year. As of the 29th of November 2024, Non Current Assets Total is likely to grow to about 5.2 M, while Other Assets are likely to drop (44.7 K).As of the 29th of November 2024, Common Stock Shares Outstanding is likely to drop to about 23.7 M
Telomir Pharmaceuticals, Workforce Comparison
Telomir Pharmaceuticals, Common is rated third in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 99,879. Telomir Pharmaceuticals, adds roughly 1.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Telomir Pharmaceuticals, Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Telomir Pharmaceuticals, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Telomir Pharmaceuticals,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Telomir Pharmaceuticals, insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Yanez Michelle over three months ago Acquisition by Yanez Michelle of 200000 shares of Telomir Pharmaceuticals, at 5.02 subject to Rule 16b-3 | ||
Bay Shore Trust over six months ago Purchase by Bay Shore Trust of 49000 shares of Telomir Pharmaceuticals | ||
Bay Shore Trust over six months ago Telomir Pharmaceuticals exotic insider transaction detected |
Telomir Pharmaceuticals, Notable Stakeholders
A Telomir Pharmaceuticals, stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Telomir Pharmaceuticals, often face trade-offs trying to please all of them. Telomir Pharmaceuticals,'s stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Telomir Pharmaceuticals,'s stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| MD ODonnell | Chief Cofounder | Profile | |
| MD Chapman | Chairman CoFounder | Profile | |
| Erez Aminov | Chairman CEO | Profile | |
| Nathen CPA | Treasurer, CFO | Profile | |
| Christos Esq | General Director | Profile | |
| Itzchak Angel | Chief Advisor | Profile | |
| Michelle MBA | Chief Officer | Profile |
About Telomir Pharmaceuticals, Management Performance
The success or failure of an entity such as Telomir Pharmaceuticals, often depends on how effective the management is. Telomir Pharmaceuticals, management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Telomir management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Telomir management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.74) | (2.88) | |
| Return On Capital Employed | (1.15) | (1.09) | |
| Return On Assets | (2.74) | (2.88) | |
| Return On Equity | (3.80) | (3.61) |
Telomir Pharmaceuticals, Workforce Analysis
Traditionally, organizations such as Telomir Pharmaceuticals, use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Telomir Pharmaceuticals, within its industry.Telomir Pharmaceuticals, Manpower Efficiency
Return on Telomir Pharmaceuticals, Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 13.1M | |
| Net Loss Per Executive | 1.9M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telomir Pharmaceuticals, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Telomir Pharmaceuticals,. If investors know Telomir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Telomir Pharmaceuticals, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.63) | Return On Assets (0.84) | Return On Equity (6.87) |
The market value of Telomir Pharmaceuticals, is measured differently than its book value, which is the value of Telomir that is recorded on the company's balance sheet. Investors also form their own opinion of Telomir Pharmaceuticals,'s value that differs from its market value or its book value, called intrinsic value, which is Telomir Pharmaceuticals,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Telomir Pharmaceuticals,'s market value can be influenced by many factors that don't directly affect Telomir Pharmaceuticals,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Telomir Pharmaceuticals,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Telomir Pharmaceuticals, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Telomir Pharmaceuticals,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.